Evan S Dellon
Overview
Explore the profile of Evan S Dellon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
476
Citations
12687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reed C, LaFata S, Gee T, Thel H, Cameron B, Xue A, et al.
Clin Gastroenterol Hepatol
. 2025 Mar;
PMID: 40074050
Background And Aims: The index of severity for eosinophilic esophagitis (I-SEE) grades eosinophilic esophagitis (EoE) severity across several domains. We assessed associations between EoE features and severity by I-SEE at...
2.
Ketchem C, Jensen E, Dai X, Anderson C, Kodroff E, Strobel M, et al.
Dis Esophagus
. 2025 Mar;
38(1).
PMID: 40036388
Little is known about the extent or importance of overlapping gastrointestinal (GI) tract involvement in eosinophilic gastrointestinal diseases (EGIDs), how presentations differ by areas of involvement, and whether overlap impacts...
3.
4.
5.
Thel H, Borinsky S, LaFata S, Gee T, Cameron B, Xue A, et al.
Dig Dis Sci
. 2025 Feb;
PMID: 39960589
Background: Untreated eosinophilic esophagitis (EoE) can result in the development of fibrostenosis over time, but there are few data on whether successful treatment in childhood decreases this risk as children...
6.
Dellon E, Katzka D, Mukkada V, Collins M, Falk G, Richmond C, et al.
Clin Gastroenterol Hepatol
. 2025 Feb;
PMID: 39954913
Background & Aims: We investigated the long-term safety and efficacy of budesonide oral suspension (BOS) in eosinophilic esophagitis (EoE). Methods: This study (SHP621-303) was a 4-year, phase 3, open-label study...
7.
Xue A, LaFata S, Gee T, Thel H, Cameron B, Kiran A, et al.
Gastro Hep Adv
. 2025 Feb;
4(3):100585.
PMID: 39926206
No abstract available.
8.
Peery A, Murphy C, Anderson C, Jensen E, Deutsch-Link S, Egberg M, et al.
Gastroenterology
. 2025 Feb;
PMID: 39920892
Background: A contemporary report describing the burden and expenditures of gastrointestinal (GI) diseases can be helpful for policy makers, administrators, and researchers. Using the most recent data, we estimated the...
9.
Bredenoord A, Dellon E, Schlag C, Cianferoni A, Xia C, Pela T, et al.
Expert Rev Gastroenterol Hepatol
. 2025 Feb;
19(2):197-209.
PMID: 39909733
Background: Standard treatments for eosinophilic esophagitis (EoE) may present adherence, tolerance, and efficacy challenges. Dupilumab 300 mg weekly is approved for the treatment of EoE in patients ≥ 1 year...
10.
Dellon E, Kosloski M, Shabbir A, Glotfelty L, Xu C, Kamal M
Clin Transl Gastroenterol
. 2025 Jan;
16(1):e00793.
PMID: 39853721
Introduction: We assessed potential mechanisms behind the requirement for more frequent dupilumab dosing in eosinophilic esophagitis (EoE) compared with other approved indications. Methods: Results for the phase 3 LIBERTY EoE...